Oct 3, 2023 · This week, the World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) provided important recommendations for the use of QDENGA in preventing dengue,” said Gary Dubin, M.D., president of the Global Vaccine Business Unit at Takeda.

Dec 8, 2022 · The double-blind, randomized, placebo-controlled Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial is evaluating the safety and efficacy of two doses of TAK-003 in the prevention of laboratory-confirmed symptomatic dengue fever of any severity and due to any of the four dengue virus serotypes in children and ...

Jul 11, 2023 · Takeda's tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “backbone” for all four vaccine viruses. 2 Clinical Phase 2 data in children and adolescents showed that TAK-003 induced immune responses against all four dengue serotypes, in both seropositive and seronegativ...

May 15, 2024 · A new vaccine for dengue received prequalification from the World Health Organization (WHO) on 10 May 2024. TAK-003 is the second dengue vaccine to be prequalified by WHO. Developed by Takeda, it is a live-attenuated vaccine containing weakened versions of the four serotypes of the virus that cause dengue.

TAK-003 is a live attenuated tetravalent dengue vaccine developed by Takeda Vaccines (Cambridge, MA, USA). Chimeric serotype 1, 3, and 4 dengue viruses were created by substituting pre-membrane and envelope genes of the DENV-2 backbone with those of the corresponding serotype.

We aimed to evaluate the long-term efficacy and safety of two doses of the tetravalent dengue vaccine TAK-003 in preventing symptomatic dengue disease of any severity and due to any dengue virus (DENV) serotypes in children and adolescents.

Aug 24, 2022 · Conclusions: TAK-003 was efficacious against symptomatic dengue over 3 years. Efficacy declined over time but remained robust against hospitalized dengue. A booster dose evaluation is planned. Trial registration: ClinicalTrials.gov NCT02747927. Keywords: children; dengue; efficacy; safety; vaccine. © The Author (s) 2021.

Oct 14, 2022 · Dengue Tetravalent Vaccine (Live, Attenuated) Takeda provides protection against fever and hospitalisation resulting from dengue disease caused by any of the 4 dengue virus serotypes. Side effects are mostly mild to moderate in severity and disappear within a few days.

Nov 6, 2019 · We present primary efficacy data from part 1 of an ongoing phase 3 randomized trial of a tetravalent dengue vaccine candidate (TAK-003) in regions of Asia and Latin America in which the...

May 15, 2024 · The World Health Organization (WHO) today announced that it has prequalified a second dengue vaccine, TAK-003, known as Qdenga and developed by Takeda. Qdenga is a live-attenuated vaccine that contains weakened versions of all four dengue serotypes.